The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines.
作者信息
Buettner Stefan, Groot Koerkamp Bas
机构信息
Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
出版信息
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):244-247. doi: 10.21037/hbsn-23-30. Epub 2023 Mar 20.
Abstract
摘要
相似文献
1
The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines.日本肝内胆管癌临床实践指南：与西方指南的比较。
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):244-247. doi: 10.21037/hbsn-23-30. Epub 2023 Mar 20.
2
Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma--focus on East and South-Eastern Asia.肝内胆管癌和肝外胆管癌发病率的比较——聚焦于东亚和东南亚地区。
Asian Pac J Cancer Prev. 2010;11(5):1159-66.
3
[International comparison of radiological aspects of the new German S3 guideline on hepatocellular carcinoma and intrahepatic cholangiocarcinoma].[德国关于肝细胞癌和肝内胆管癌的新S3指南放射学方面的国际比较]
Radiologe. 2022 Mar;62(3):253-262. doi: 10.1007/s00117-022-00968-x. Epub 2022 Feb 18.
4
Predictive factors for subsequent intrahepatic cholangiocarcinoma associated with hepatolithiasis: Japanese National Cohort Study for 18 years.与肝胆管结石相关的肝内胆管癌的预测因素：18 年日本全国队列研究。
J Gastroenterol. 2022 May;57(5):387-395. doi: 10.1007/s00535-022-01868-6. Epub 2022 Mar 31.
5
Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma.成纤维细胞生长因子受体 2（FGFR2）融合在日本肝内胆管癌患者中的研究。
Jpn J Clin Oncol. 2021 May 28;51(6):911-917. doi: 10.1093/jjco/hyab029.
6
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.肝内胆管癌诊断和管理指南
J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. Epub 2014 Mar 27.
7
Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma.肝内胆管癌的手术和肝动脉灌注治疗。
Surgery. 2023 Jul;174(1):113-115. doi: 10.1016/j.surg.2023.01.019. Epub 2023 Mar 9.
8
[A comparison of current guidelines for the management of intrahepatic cholangiocarcinoma worldwide].[全球肝内胆管癌当前管理指南的比较]
Zhonghua Wai Ke Za Zhi. 2023 Feb 23;61(4):297-304. doi: 10.3760/cma.j.cn112139-20221125-00495.
9
Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma.肝门部胆管癌根治性切除术后累及肝门的肝内胆管细胞癌的围手术期和长期预后：与周围型肝内胆管细胞癌和肝门部胆管癌的比较。
Surgery. 2018 May;163(5):1114-1120. doi: 10.1016/j.surg.2018.01.001. Epub 2018 Feb 2.
10
Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan.R0 切除术后肝内胆管细胞癌手术切缘宽度的影响：日本肝癌研究组的全国性调查。
Surgery. 2020 May;167(5):793-802. doi: 10.1016/j.surg.2019.12.009. Epub 2020 Feb 8.
引用本文的文献
1
Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.关于肝癌患者肝移植后免疫治疗反应的当前知识。
J Liver Transpl. 2025 Aug;19. doi: 10.1016/j.liver.2025.100285. Epub 2025 Jun 6.
2
Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes.拉丁美洲的胆管癌：一项多中心观察性研究对肿瘤表现和预后方面的种族差异发出警示。
Lancet Reg Health Am. 2024 Nov 25;40:100952. doi: 10.1016/j.lana.2024.100952. eCollection 2024 Dec.
3
The fibrosis-4 index is a prognostic factor for cholangiocarcinoma patients who received immunotherapy.纤维 4 指数是接受免疫治疗的胆管癌患者的预后因素。
Front Immunol. 2024 May 10;15:1376590. doi: 10.3389/fimmu.2024.1376590. eCollection 2024.
本文引用的文献
1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
2
Major complications and mortality after resection of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis.肝内胆管癌切除术后的主要并发症及死亡率：一项系统评价和荟萃分析。
Surgery. 2023 Apr;173(4):973-982. doi: 10.1016/j.surg.2022.11.027. Epub 2022 Dec 27.
3
Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?肝内胆管癌的手术切除——我们真的能通过切除更多淋巴结来提高生存率吗？
J Hepatol. 2023 Feb;78(2):235-237. doi: 10.1016/j.jhep.2022.12.003. Epub 2022 Dec 23.
4
FAPI PET versus FDG PET, CT or MRI for Staging Pancreatic-, Gastric- and Cholangiocarcinoma: Systematic Review and Head-to-Head Comparisons of Diagnostic Performances.FAPI PET与FDG PET、CT或MRI用于胰腺癌、胃癌和胆管癌分期：系统评价及诊断性能的直接比较
Diagnostics (Basel). 2022 Aug 12;12(8):1958. doi: 10.3390/diagnostics12081958.
5
Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.日本肝癌研究组肝内胆管癌临床实践指南
Liver Cancer. 2022 Feb 23;11(4):290-314. doi: 10.1159/000522403. eCollection 2022 Jul.
6
Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).随机 III 期研究：吉西他滨、顺铂加 S-1 对比吉西他滨、顺铂治疗晚期胆道癌（KHBO1401- MITSUBA）。
J Hepatobiliary Pancreat Sci. 2023 Jan;30(1):102-110. doi: 10.1002/jhbp.1219. Epub 2022 Aug 9.
7
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study.随机 III 期 BILCAP 研究的长期结果和探索性分析。
J Clin Oncol. 2022 Jun 20;40(18):2048-2057. doi: 10.1200/JCO.21.02568. Epub 2022 Mar 22.
8
Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.不可切除的肝内胆管癌的肝动脉灌注化疗泵化疗：系统评价和荟萃分析。
Ann Surg Oncol. 2022 Sep;29(9):5528-5538. doi: 10.1245/s10434-022-11439-x. Epub 2022 Mar 16.
9
Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis.局部区域治疗在肝内胆管细胞癌患者中的应用：一项系统评价和荟萃分析。
Cancer Treat Rev. 2021 Sep;99:102258. doi: 10.1016/j.ctrv.2021.102258. Epub 2021 Jul 7.
10
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.晚期胆管癌二线FOLFOX化疗与积极症状控制的对比研究（ABC-06）：一项3期、开放标签、随机对照试验
Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.
Zotero 插件